BIO thanks retiring FDA Commissioner.
Share:
Press Release Summary:
BIO President and CEO Jim Greenwood issued statement regarding announced retirement of Dr. Margaret Hamburg. Dr. Hamburg presided over implementation of Food and Drug Administration Safety and Innovation Act and successful launch of breakthrough therapy designation program and other expansions of expedited approval pathways. These programs have proven invaluable in bringing groundbreaking new therapies to patients more efficiently, while maintaining FDA’s high standards for safety and efficacy.
Original Press Release:
BIO Thanks Retiring FDA Commissioner Dr. Margaret Hamburg for Her Years of Commendable Service
WASHINGTON -- Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood issued the following statement today regarding the announced retirement of Food and Drug Administration (FDA) Commissioner Dr. Margaret Hamburg:
“We look forward to continuing to work with Dr. Hamburg and her successor to ensure that the FDA’s regulatory capabilities and science continue to keep pace with the tremendous progress taking place in biotechnology innovation.”
“BIO extends our thanks and gratitude to Dr. Margaret Hamburg for her nearly six years of public service as the Commissioner of the FDA, a job that carries tremendous responsibility in protecting public health and advancing biomedical and agricultural innovation. Dr. Hamburg fulfilled these duties well and served at a time of historic advances in biotechnology and regulatory science.
“Of particular note, Dr. Hamburg presided over the implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) and the successful launch of the breakthrough therapy designation program and other expansions of expedited approval pathways. These programs have proven invaluable in bringing groundbreaking new therapies to patients more efficiently, while maintaining the FDA’s high standards for safety and efficacy. In 2014, the FDA approved more than 40 new drugs, the most in nearly two decades.
“We look forward to continuing to work with Dr. Hamburg and her successor to ensure that the FDA’s regulatory capabilities and science continue to keep pace with the tremendous progress taking place in biotechnology innovation.”
About BIO
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.
Upcoming BIO Events
BIO CEO & Investor Conference
February 9-10, 2015
New York City, NY
BIO-Europe Spring
March 9-11, 2015
Paris, France
BIO Asia International Conference
March 24-25, 2015
Tokyo, Japan
BioEquity Europe
May 19-20, 2015
Vienna, Austria
BIO International Convention
June 15-18, 2015
Philadelphia, PA
Contacts
Biotechnology Industry Organization (BIO)
Daniel Seaton, 202-470-5207
Web: www.bio.org
Blog: www.biotech-now.org
Twitter: @IAmBiotech
